Akebia Therapeutics, a US-based biotech company spun out from consumer goods company Procter & Gamble, has raised $41m in its series C round. Satter Investment Management, a private equity firm, led the most recent funding round, which also included venture capital firms Triathlon Medical Ventures, CincyTech, Blue Chip Venture Company, Queen City Angels and Fort…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
